Posted in | News | Nanomedicine

Ultra-Small Nanomedicines Show Potential for Oligonucleotide Delivery to Intractable Cancers

Editorial Checklist Reviewed
Jan 20 2021

Related Stories

Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.

Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the blood circulation.

The ultra-small size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues.

Clinical trials and preclinical studies using the developed ultra-small nanomedicines are proceeding for cancer therapy.

Published in the website of Journal of Controlled Release on January 6.

https://doi.org/10.1016/j.jconrel.2021.01.001

Source:

https://iconm.kawasaki-net.ne.jp/en/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
(Logout)
Your comment type
Submit

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback